testosterone replacement therapy (TRT) and the potential for adverse cardiovascular outcomes associated with TRT. Briefing docs Related tickers: ( ABBV +0.1% ) ( LLY -0.1% ) ( AUXL -2.9% ) ( TEVA -1.4% ) Post your comment!
department stores – M ; discount – BURL ; avoid women’s apparel and teen retailers]. Bearish stories: Auxilium Pharma [ AUXL ; money losing company is doing a tax-inversion by buying Canadian QLTI ; pg 18]. Pg 30: New Constructs website tracks and
Auxilium Pharma (NASDAQ: AUXL ) +3% AH after announcing a corporate ..... drive sustainable earnings growth." AUXL plans include a ~30% workforce reduction ..... least $75M/year in cost savings. AUXL expects to record restructuring related
replacement products. Testosterone replacement gel products like AbbVie's (NYSE: ABBV ) Androgel and Auxilium's (NASDAQ: AUXL ) Testim became huge sellers in the last decade and there have been a number of new competitors, both gels and injectables
in the appearance of cellulite, measured by the trial endpoints. BioSpecifics' strategic partner Auxilium Pharmaceuticals (NASDAQ: AUXL ) conducted the trial, the primary endpoint of which was an investigator and a patient score on the
Aug 21 (Reuters) - Auxilium Pharmaceuticals Inc said two doses of its drug to smoothen cellulite were statistically significant in a mid-stage study, sending its shares up nearly 8 percent.
Auxilium Pharmaceuticals (NASDAQ: AUXL ) announces the results from a Phase 2a clinical trial evaluating the safety and efficacy of injections of collagenase clostridium
Aug 21 (Reuters) - Auxilium Pharmaceuticals Inc said its experimental drug showed significant improvement in smoothing cellulite in a mid-stage study.
By Alexander Maxwell : Having previously updated the investment community in part 3 of my Biotechnology Catalysts series, the purpose of this article is to help give investors an idea of the upcoming biotechnology catalysts through the end of September. It can be hard for investors to be able to ...
and controls patents and patent applications for XIAFLEX and is entitled to get royalties until 2028 from Auxilium (NASDAQ: AUXL ) for Dupuytren's Contracture, Peyronie's Disease, Frozen Shoulder and Cellulite. Thomas L. Wegman, President of BioSpecifics